drugset / Trial / NCT06098898
Safety and Efficacy of NK510 to Treat Gastric Cancer
Phase 0
Unknown
9 enrolled
Base Therapeutics (Shanghai) Co., Ltd.
Shanghai 10th People's Hospital · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced gastric cancer.NK510 will be administered in combination with PD-1 blockade or monoclonal anti-HER2 antibody. Patients are required to undergo a biopsy for confirmation of tumor PD-L1 and HER2 expression and. The safety and efficacy of this treatment will be evaluated.
Timeline
- Start
- 2023-11-01
- Primary completion
- 2024-11-01
- Completion
- 2024-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | — | — |
| Subject | NK510 | Cell therapy | 9e+09 cells | Intravenous |
| Subject | NK510 | Cell therapy | 1.2e+10 cells | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | — | — |
| Subject | Trastuzumab | Monoclonal antibody | — | — |